The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Microbiology
Volume 14 - 2024 |
doi: 10.3389/fcimb.2024.1390098
This article is part of the Research Topic Comprehensive Insights into Respiratory Virus Pathogenesis, Prophylaxis, Clinical Manifestations, and Diagnostics View all 5 articles
Efficacy of Azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multiple-centers study
Provisionally accepted- 1 The Fourth Affiliated Hospital of Soochow University, Suzhou, China
- 2 The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
- 3 The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China
As the first Chinese oral anti-COVID-19 drug , Azvudine showed substantial clinical benefits to viral clearance and prognosis in the mild and common COVID-19 patients. However, there was no evidence in severe hospitalized COVID-19 patients. In this multiple-centers study, We analyzed 209 hospitalized severe COVID-19 patients in four hospitals. All the clinical data and the 28-days composite outcomes were recorded. All patients were divided into two groups according to the drugs: dexamethasone (DXM) group, Azvudine plus dexamethasone (AZV+DXM) group. There was no difference in sex, age, BMI, underlying diseases between two groups. The ratio of 28-days composite outcome was lower for AZV+DXM group than that in DXM group (16.97% vs. 31.82%, P=0.029). The viral clearance time was shorter in AZV+DXM group than in DXM group (7.32±2.57days vs. 8.55±2.34 days, P=0.017). The PaO2 /FiO2 levels at day 5 (258.89±55.22 vs 233.12±60.51, P=0.026) and day 10 (289.48±44.09 vs. 261.52±37.34, P=0.015) were higher in AZV+DXM group than DXM group. However, the hospitalized duration of two groups were similar. Cox analysis showed the benefit of AZV+DXM in sub-group of ≥65years, MODS, cerebrovascular disease, CRP ≥70mg/L, d-dimer ≥1µg/L. Our study firstly indicated that Azvudine plus dexamethasone treatment might benefit to severe Omicron infected patients compared with dexamethasone treatment. This results, as least partly, demonstrated the necessity of antiviral treatment in severe patients.
Keywords: COVID-19, omicron, azvudine, Dexamethasone, Severe disease
Received: 22 Feb 2024; Accepted: 31 Oct 2024.
Copyright: © 2024 Zhang, Wei, Su, Jiang, Xu and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Meng-Lan Zhang, The Fourth Affiliated Hospital of Soochow University, Suzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.